Lupin 2024

PCMA releases new policy recommendations to remove barriers to biosimilars

PCMA releases new policy recommendations to remove barriers to biosimilars, lower drug costs

PCMA releases new policy recommendations to remove barriers to biosimilars, lower drug costs

WASHINGTON — Pharmacy benefit managers, PBMs, support the proliferation and use of biosimilars. A robust biosimilar market will increase competition for biologic drugs and provide added choice and flexibility for health plan sponsors, allowing PBMs to leverage competition more effectively to further reduce drug costs. Today, the Pharmaceutical Care Management Association (PCMA) is releasing policy

PP_1170x120_10-25-21